Search results
Bayer filed a suit for infringement against CIPLA before the Indian courts (not the subject of this case summary). At the time of the suit, Bayer charged 280,438 INR (~ US $ 5280) per month compared to CIPLA's generic version marketed at 27,960 INR (~ US $ 525) for the same amount of tablets.
18 wrz 2022 · Case Name: Bayer Corporation vs Union of India (2014) Bombay HC Writ Petition No.1323 OF 2013. Court: Bombay High Court. Bench. Mohit S. Shah, C.J. S. Sanklecha, J. Parties Petitioner. Bayer Corporation, A Corporation Organized under the laws of the State of Indiana, Unites States of America-100 Bayer Road, Pittsburgh, PA 1505-9741, United ...
Facts. German company Bayer Corp. (Bayer) (plaintiff) patented a cancer drug called Nexavar. India’s patent office granted a compulsory license to make and sell Nexavar in India to an Indian company called Natco Pharma Ltd. (Natco) after Bayer refused to grant Natco a license voluntarily.
15 lip 2014 · Explore the legal case of Bayer Corporation vs. Union of India & Ors. Delve into the case details, arguments presented, and its significance. Gain insights into the legal intricacies surrounding this case and its potential impact on relevant industries or legal precedents.
14 sie 2024 · Key legal issues discussed. 1. Did the applicant (Natco) make efforts to obtain a voluntary licence from the Patent holder (Bayer) as required under Section 84 (6) (iv) of the Patents Act, 1970? Yes. There are two conditions precedent to consider an application for Compulsory Licence.
15 lip 2014 · In the case of Bayer Corporation vs Union of India, a significant legal battle unfolded in the Indian courts, with far-reaching implications for the pharmaceutical industry and the application of patent law.
The very first case that happens to give a liberal and more flexible interpretation of Indian patent linkage in accordance with its compulsory license regime and application of bolar provision was the case of Bayer Corporation v. Union of India and Ors. Background: Bayer Corporation, the petitioner in the present case, a company based in USA ...
